New clinical evidence: DILAPAN-S meta-analysis

Date 26.02.2025

Has DILAPAN-S a potential to reduce caesarean section rates?

We are keen to annouce that the first DILAPAN-S meta-analysis providing a comprehensive evaluation of four major randomized trials involving over 1,700 women.

Saad et al.: Dilapan-S vs standard methods for cervical ripening in term pregnancies: An individual patient data meta-analysis. AJOG MFM, December 2024

DOI: 10.1016/j.ajogmf.2024.101583

Key findings

No significant difference in Caesarean section rates between DILAPAN-S and other methods, however subgroup analysis demonstrated significant interaction with parity with a 99% probability of lowering risk of cesarean rates among multiparous women induced with Dilapan-S.
Lower complication rates during the ripening period with DILAPAN-S (19% vs 47% in standard methods).
Significantly higher patient satisfaction due to lower pain levels, greater mobility, and the ability to rest, eat, and sleep.

A win for mothers and healthcare systems

The potential of DILAPAN-S in terms of safety and maternal preference has been consistently reinforced by ongoing clinical studies. Now, a new and significant aspect emerges – the potential to reduce the rate of caesarean sections. This finding has far-reaching implications, not only for the safety of childbirth but also for healthcare cost-effectiveness, as a lower caesarean section rate translates into substantial savings for healthcare systems.

Most importantly, achieving a vaginal birth carries a profound human dimension – for both mother and child. For the mother, it can mean greater birth satisfaction, a shorter recovery period, and a lower risk of complications in future pregnancies. For the baby, it may support better postnatal adaptation and offer potential long-term health benefits.

For further details, visit https://www.dilapan.com/healthcare-professionals/resources/